Adaptimmune Therapeutics Plc

NASDAQ: ADAP
$0.64
-$0.03 (-4.2%)
Closing Price on November 21, 2024

ADAP Stock Chart and Intraday Price

ADAP Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, GB
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 361.12M USD
Shares Outstanding 227,122,000
Adaptimmune Therapeutics Plc is a biopharmaceutical company focused on developing novel cell therapies for cancer patients. With operations in the US and UK, it's advancing treatments through clinical trials, including therapies for synovial sarcoma and ovarian cancer. The company collaborates with industry leaders like Genentech and F. Hoffman-La Roche to create both personalized and universal T-cell therapies. Founded in 2008 and based in Abingdon, UK, Adaptimmune also works closely with academic institutions and other biotech firms to innovate cancer treatment.

ADAP Articles

Dollar General, HP, Johnson & Johnson and More Friday Afternoon Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Dollar General, Johnson & Johnson, HP and Teladoc.
Chris Lange
Published: